Hemostasis Today
NewsFeed
Headlines Hematology Health Medicine VTE ASH Plasma Donation
August, 2026
August 2026
M T W T F S S
 12
3456789
10111213141516
17181920212223
24252627282930
31  
Shantelle Kuria – von Willebrand Disease: Complex Protein, Difficult Market
Shantelle Kuria/LinkedIn
Nov 27, 2025, 04:58

Shantelle Kuria – von Willebrand Disease: Complex Protein, Difficult Market

Shantelle Kuria, Master of Science in Molecular Medicine at Imperial College London, posted on LinkedIn:

”Ever cut your finger while cooking… and watched it bleed for a moment before it just… stops?

That tiny, almost forgettable moment is driven by a proetin most people have never heard of: von Willebrand factor (VWF).

A few weeks ago, I was exploring VWF biology in an MSc lecture, at the very same time, I was supporting an early-phase clinical trial in VWD in my CRO role.

Two worlds…academic and operational…aligning around the same protein.

And it made me ask:

  • What actually drives innovation in bleeding disorders?
  • And why is a rare disease like VWD suddenly gaining strategic momentum across industry?

In the full piece, I unpack:

  • Science – why VWF’s chaotic multimer structure matters.
  • Early-Phase Reality – why VWD trials are some of the hardest to run.
  • Market Shift – how recombinant and engineered designs are reshaping a quiet market.
  • IP and Strategy – how manufacturing patents + orphan exclusivity shape who can compete.

Full article here.

(Would love to hear your take on it.)”

von Willebrand

Stay updated with Hemostasis Today.

Biomanufacturing bleeding disorders Clinical Research Drug Development Health Hematology Hemostasis Hemostasis Today Imperial College London innovation Medicine Molecular Medicine Rare Disease research Shantelle Kuria thrombosis Von Willebrand Disease Von Willebrand Factor VWD VWF
NewsFeed